Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Sponsor: Ra Pharmaceuticals, Inc.
Terminated
After careful consideration, UCB has decided to no longer pursue PNH as a potential indication for zilucoplan.
Other terminated trials from Ra Pharmaceuticals, Inc.
More terminations from Ra Pharmaceuticals, Inc.
Other Paroxysmal Nocturnal Hemoglobinuria (PNH) trials with similar outcome
Listed as NCT03225287, this PHASE2 trial focuses on Paroxysmal Nocturnal Hemoglobinuria (PNH) and remains terminated or withdrawn. Sponsored by Ra Pharmaceuticals, Inc., it has been updated 19 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
19 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Oct 2023 [monthly]
Terminated PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Terminated PHASE2
▶ Show 14 earlier versions
-
May 2022 — Sep 2022 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Apr 2022 — May 2022 [monthly]
Completed PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ra Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .